Boston Scientific confirmed July 30 that its Costa Rican operations will be affected by a global corporate restructuring [1].
The move signals a significant shift in the company's operational footprint in Central America. Because Costa Rica is a major hub for medical device manufacturing, these cuts may impact the local labor market and regional supply chains.
The restructuring is part of a broader effort to reduce costs and realign operations across the company's international sites [1, 2]. While the company has not disclosed the specific number of employees who will be fired or the exact timeline for the layoffs, it has confirmed that the Costa Rican sites are included in the plan [1, 2].
To manage the workforce reduction, Boston Scientific has set aside $300 million for employee termination benefits [1]. This fund is intended to cover the costs associated with the global restructuring process as the firm streamlines its organizational structure, a move that also impacts operations in Ireland [2].
Company officials said they did not specify which particular facilities in Costa Rica will see the largest reductions. The lack of granular detail regarding the scale of the layoffs leaves the exact impact on the local workforce unclear [1].
“Boston Scientific confirmed that its Costa Rica operations will be affected by a global restructuring.”
The restructuring indicates that Boston Scientific is prioritizing lean operations and cost efficiency over aggressive expansion in its current manufacturing hubs. By allocating substantial funds for termination benefits, the company is preparing for a significant reduction in headcount to protect its bottom line during a period of operational realignment.
